Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

CONCLUSIONS:Treatment with ART and R-HD-MTX is associated with a high response rate, CD4+ immune reconstitution, preserved cognition, and improved OS, even in a high-risk patient population.DisclosuresUldrick: Celgene: Patents & Royalties: 10,001,483 B2; Celgene: Research Funding; Merck: Research Funding. Yarchoan: NIH: Patents & Royalties: Patents on IL-12 for KS and cereblon-binding drugs for KSHV diseases. Spouse has patent on KSHV IL-6. Patents assigned to DHHS/NIH.; Celgene Corp.: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Lurain, K., Uldrick, T. S., Goncalves, P. H., Ramaswami, R., Polizzotto, M. N., Widell, A., Steinberg, S. M., Jaffe, E. S., Pittaluga, S., Stetler-Stevenson, M., Yuan, C. M., Little, R. F., Yarchoan, R. Tags: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster II Source Type: research